BC Week In Review | Nov 3, 2008
Clinical News

DPS-101: Phase IIb data

A double-blind, European Phase IIb trial in 168 patients showed that the highest dose of DPS-101 met all the primary and secondary endpoints. Patients received 0.05%, 0.1%, 0.7% or 1.4% nicotinamide plus 0.005% calcipotriol twice...
Items per page:
1 - 1 of 1